

Juan Eduardo Megã-as-Vericat

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2571534/publications.pdf>

Version: 2024-02-01

32
papers

452
citations

687220

13
h-index

752573

20
g-index

32
all docs

32
docs citations

32
times ranked

805
citing authors

#	ARTICLE	IF	CITATIONS
1	Baricitinib against severe COVID-19: effectiveness and safety in hospitalised pretreated patients. <i>European Journal of Hospital Pharmacy</i> , 2022, 29, e41-e45.	0.5	9
2	Treatment patterns and outcomes of 2310 patients with secondary acute myeloid leukemia: a PETHEMA registry study. <i>Blood Advances</i> , 2022, 6, 1278-1295.	2.5	29
3	Emerging FLT3 inhibitors for the treatment of acute myeloid leukemia. <i>Expert Opinion on Emerging Drugs</i> , 2022, 27, 1-18.	1.0	7
4	Systematic Review of Pharmacogenetics of ABC and SLC Transporter Genes in Acute Myeloid Leukemia. <i>Pharmaceutics</i> , 2022, 14, 878.	2.0	5
5	Healthcare Resource Utilization among Patients between 60-75 Years with Secondary Acute Myeloid Leukemia Receiving Intensive Chemotherapy Induction: A Spanish Retrospective Observational Study. <i>Cancers</i> , 2022, 14, 1921.	1.7	1
6	Impact of combinations of single-nucleotide polymorphisms of anthracycline transporter genes upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2021, 62, 659-668.	0.6	10
7	Gilteritinib use in the treatment of relapsed or refractory acute myeloid leukemia with a FLT3 mutation. <i>Future Oncology</i> , 2021, 17, 215-227.	1.1	0
8	Healthcare resource utilization in adult patients with relapsed/refractory FLT3 mutated acute myeloid leukemia: A retrospective chart review from Spain. <i>European Journal of Haematology</i> , 2021, 106, 724-733.	1.1	1
9	A phase I trial of selinexor plus FLAG-Ida for the treatment of refractory/relapsed adult acute myeloid leukemia patients. <i>Annals of Hematology</i> , 2021, 100, 1497-1508.	0.8	7
10	Extracorporeal photopheresis vs standard therapies for steroid-refractory chronic graft-versus-host disease: Pharmacoeconomic assessment of hospital resource use in Spain. <i>Journal of Clinical Apheresis</i> , 2021, 36, 612-620.	0.7	2
11	Evolving patterns of care and outcomes in relapsed/refractory FLT3 mutated acute myeloid leukemia adult patients. <i>Leukemia and Lymphoma</i> , 2021, 62, 2727-2736.	0.6	0
12	Characteristics, clinical outcomes, and risk factors of SARS-COV-2 infection in adult acute myeloid leukemia patients: experience of the PETHEMA group. <i>Leukemia and Lymphoma</i> , 2021, 62, 2928-2938.	0.6	21
13	Clinical benefits of a Bayesian model for plasma-derived factor VIII/WWF after one year of pharmacokinetic-guided prophylaxis in severe/moderate hemophilia A patients. <i>Thrombosis Research</i> , 2021, 205, 99-105.	0.8	4
14	Monitoring coagulation factors during surgery. A systematic review. <i>Farmacia Hospitalaria</i> , 2021, 45, 94-101.	0.6	0
15	Development and Validation of a Population-Pharmacokinetic Model for Rurioctacog Alfa Pegol (Adynovate®): A Report on Behalf of the WAPPS-Hemo Investigators Ad Hoc Subgroup. <i>Clinical Pharmacokinetics</i> , 2020, 59, 245-256.	1.6	18
16	Clinical, pharmacokinetic and economic analysis of the first switch to an extended half-life factor IX (albutrepenonacog alfa, rFIX-FP) in Spain. <i>BMJ Case Reports</i> , 2020, 13, e234142.	0.2	4
17	Drug-drug interactions of newly approved small molecule inhibitors for acute myeloid leukemia. <i>Annals of Hematology</i> , 2020, 99, 1989-2007.	0.8	26
18	Precision medicine in acute myeloid leukemia: where are we now and what does the future hold?. <i>Expert Review of Hematology</i> , 2020, 13, 1057-1065.	1.0	5

#	ARTICLE	IF	CITATIONS
19	Quality of electronic treatment records and adherence to prophylaxis in haemophilia and von Willebrand disease: Systematic assessments from an electronic diary. <i>Haemophilia</i> , 2020, 26, 999-1008.	1.0	7
20	Tyrosine kinase inhibitors for acute myeloid leukemia: A step toward disease control?. <i>Blood Reviews</i> , 2020, 44, 100675.	2.8	23
21	<p>IDH1-mutated relapsed or refractory AML: current challenges and future prospects</p>; <i>Blood and Lymphatic Cancer: Targets and Therapy</i> , 2019, Volume 9, 19-32.	1.2	24
22	Daunorubicin and cytarabine for certain types of poor-prognosis acute myeloid leukemia: a systematic literature review. <i>Expert Review of Clinical Pharmacology</i> , 2019, 12, 197-218.	1.3	15
23	Crossâ€sectional comparative study of pharmacokinetics and efficacy between sucroseâ€formulated recombinant factor VIII (Kogenate^{Â®}) and BAY 81â€8973 (Kovaltry^{Â®}) in patients with severe or moderate haemophilia A in prophylaxis. <i>Haemophilia</i> , 2019, 25, e215-e218.	1.0	9
24	DIFFERENCES IN EX-VIVO CHEMOSENSITIVITY TO ANTHRACYCLINES IN FIRST LINE ACUTE MYELOID LEUKEMIA. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2019, 11, e2019016.	0.5	3
25	Bayesian pharmacokinetic-guided prophylaxis with recombinant factor VIII in severe or moderate haemophilia A. <i>Thrombosis Research</i> , 2019, 174, 151-162.	0.8	27
26	Salvage regimens using conventional chemotherapy agents for relapsed/refractory adult AML patients: a systematic literature review. <i>Annals of Hematology</i> , 2018, 97, 1115-1153.	0.8	81
27	Pharmacogenetics of Metabolic Genes of Anthracyclines in Acute Myeloid Leukemia. <i>Current Drug Metabolism</i> , 2018, 19, 55-74.	0.7	22
28	Pilot evaluation of home delivery programme in haemophilia. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2018, 43, 822-828.	0.7	6
29	Influence of cytarabine metabolic pathway polymorphisms in acute myeloid leukemia induction treatment. <i>Leukemia and Lymphoma</i> , 2017, 58, 2880-2894.	0.6	12
30	Impact of<i>ABC</i> single nucleotide polymorphisms upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2017, 58, 1197-1206.	0.6	33
31	Pharmacogenomics and the treatment of acute myeloid leukemia. <i>Pharmacogenomics</i> , 2016, 17, 1245-1272.	0.6	25
32	Use of 2 hydroxypropyl-beta-cyclodextrin therapy in two adult Niemann Pick Type C patients. <i>Journal of the Neurological Sciences</i> , 2016, 366, 65-67.	0.3	16